5AM Venture Management, LLC
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), 5AM Venture Management, LLC reported 21 stock positions worth $318.1 million. Its top holding was Entrada Therapeutics (TRDA) at 13.1% of the portfolio, followed by CAMP4 Therapeutics (CAMP, 11.3%) and Tyra Biosciences (TYRA, 8.5%). Compared with Q3 2025, it opened 1 new position, sold out of 5, added to 6 and reduced 2. The biggest buy was a new position in Maplight Therapeutics (MPLT) and the biggest sale an exit from Dianthus Therapeutics (DNTH).
- Most Recent 13F
- Q2 2026
- Location
- SAN FRANCISCO, CA
- CIK
- 0001799883
- Portfolio Value
- $318.1M (Q4 2025)
- SEC Filing
- 0001799883-26-000001 ↗ filed Feb 17, 2026
Holdings Value
Holdings 21 stocks · $318.1M
| TRDA Entrada Therapeutics Inc. | 13.11% | 4,056,379 | $41.7M | Reduce -4.7% |
| CAMP CAMP4 Therapeutics Corp. | 11.31% | 5,869,091 | $36.0M | No change |
| TYRA Tyra Biosciences Inc. | 8.51% | 1,029,298 | $27.1M | Add +9.6% |
| VRDN Viridian Therapeutics Inc. | 7.21% | 736,595 | $22.9M | No change |
| PHVS Pharvaris NV | 6.96% | 797,600 | $22.1M | No change |
| ERAS Erasca Inc. | 6.32% | 5,405,404 | $20.1M | No change |
| EYPT Eyepoint Inc. | 6.03% | 1,050,000 | $19.2M | No change |
| MPLT Maplight Therapeutics Inc. | 5.25% | 950,011 | $16.7M | New |
| CNTA Centessa Pharmaceuticals Ltd. | 4.57% | 580,945 | $14.5M | Reduce -14.7% |
| CLDX Celldex Therapeutics Inc. | 4.25% | 497,270 | $13.5M | No change |
| TECX Tectonic Therapeutic Inc. | 3.98% | 606,660 | $12.7M | Add +18.6% |
| ELVN Enliven Therapeutics Inc. | 3.74% | 772,477 | $11.9M | No change |
| ARTV Artiva Biotherapeutics Inc. | 3.17% | 2,353,304 | $10.1M | No change |
| SRZN Surrozen Inc. | 2.75% | 387,500 | $8.8M | Add +25.0% |
| BHVN Biohaven Ltd. | 2.62% | 738,972 | $8.3M | Add +54.3% |
| TARA Protara Therapeutic Inc. | 2.30% | 1,369,782 | $7.3M | Add +71.2% |
| GHRS GH Research PLC | 2.29% | 572,665 | $7.3M | No change |
| SKYE Skye Bioscience Inc. | 2.28% | 9,681,763 | $7.3M | No change |
| ZNTL Zentalis Pharmaceuticals Inc. | 1.68% | 3,947,913 | $5.3M | Add +705.7% |
| SLN Silence Therapeutics PLC-ADR | 0.91% | 476,200 | $2.9M | No change |
| RLYB Rallybio Corp. | 0.78% | 3,630,724 | $2.5M | No change |
Portfolio Sells Q3 2025 → Q4 2025
| DNTH Dianthus Therapeutics Inc. | Sold out | 0.00% | −5.26 |
| PRAX Praxis Precision Medicines I | Sold out | 0.00% | −3.30 |
| CNTA Centessa Pharmaceuticals Ltd. | Reduce -14.7% | 4.57% | −1.48 |
| ALEC Alector Inc. | Sold out | 0.00% | −1.08 |
| ADVM Adverum Biotechnologies Inc. | Sold out | 0.00% | −0.90 |
| MRSN Mersana Therapeutics Inc. | Sold out | 0.00% | −0.15 |
| TRDA Entrada Therapeutics Inc. | Reduce -4.7% | 13.11% | +4.07 |
Portfolio Buys Q3 2025 → Q4 2025
| MPLT Maplight Therapeutics Inc. | New | 5.25% | +5.25 |
| TYRA Tyra Biosciences Inc. | Add +9.6% | 8.51% | +3.69 |
| ZNTL Zentalis Pharmaceuticals Inc. | Add +705.7% | 1.68% | +1.40 |
| SRZN Surrozen Inc. | Add +25.0% | 2.75% | +1.29 |
| TECX Tectonic Therapeutic Inc. | Add +18.6% | 3.98% | +1.04 |
| TARA Protara Therapeutic Inc. | Add +71.2% | 2.30% | +1.02 |
| BHVN Biohaven Ltd. | Add +54.3% | 2.62% | −0.01 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 16 | $287.9M | MPLT, TYRA, TRDA, PHVS, CAMP |
| Q1 2026 | 20 | $360.2M | ERAS, TRDA, TYRA, CAMP, CNTA |
| Q4 2025 | 21 | $318.1M | TRDA, CAMP, TYRA, VRDN, PHVS |
| Q3 2025 | 25 | $273.0M | SKYE, TRDA, PHVS, CAMP, CNTA |
| Q2 2025 | 29 | $260.1M | SKYE, TRDA, DNTH, ELVN, PHVS |
| Q1 2025 | 31 | $264.4M | TRDA, ELVN, DNTH, SKYE, PHVS |
| Q4 2024 | 31 | $419.1M | TRDA, ELVN, SKYE, TECX, ARTV |
| Q3 2024 | 28 | $484.0M | TRDA, ELVN, SKYE, ARTV, DNTH |
| Q2 2024 | 28 | $447.1M | SKYE, TRDA, ELVN, DNTH, CLDX |
| Q1 2024 | 26 | $446.6M | ELVN, TRDA, DNTH, MRUS, CLDX |